Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
4-Hydroxyphenylpyruvate dioxygenase (HPPD), an essential enzyme in tyrosine catabolism, is an important target for treating type I tyrosinemia. Inhibition of HPPD can effectively alleviate the symptoms of type I tyrosinemia. However, only one commercial HPPD inhibitor, 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione (NTBC), has been available for clinical use so far. In the present study, a series of novel pyrazole-benzimidazolone hybrids were designed, synthesized and evaluated as potent human HPPD inhibitors. Most of the new compounds displayed significant inhibitory activity against the recombinant human HPPD. Moreover, compound 9l was identified as the most potent candidate with IC50 value of 0.021 μM against recombinant human HPPD, about 3-fold more potent than NTBC. Thus the pyrazole-benzimidazolone hybrid has great potential to be further developed for the treatment of type I tyrosinemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2015.01.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent hyperinsulinemic hypoglycemia of infancy treated at the Hospital Infantil de Especialidades de Chihuahua.
Bol Med Hosp Infant Mex
August 2025
Departamento de Pediatría.
Background: Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) affects between 0.5% and 5% of pediatric patients. This condition is caused by a dysfunction of pancreatic β-cells, leading to tumors and hyperinsulinism, which result in persistent hypoglycemia.
View Article and Find Full Text PDFprecision base editing to rescue mouse models of disease.
Mol Ther Nucleic Acids
September 2025
Bioengineering and Molecular Medicine Laboratory, The Children's Hospital at Westmead and the Westmead Institute for Medical Research, Westmead, NSW 2145, Australia.
CRISPR base editing enables precise, irreversible base conversions without inducing double-stranded breaks (DSBs) and has gained significant attention in recent years. By converting cytosine to thymine (C→T) or adenine to guanine (A→G), base editors (BEs) efficiently correct pathogenic single-nucleotide variants (SNVs). This review examines mouse disease models-assessing editing efficiency, phenotypic rescue, and therapeutic potential across 66 studies.
View Article and Find Full Text PDFScreening for Life: Perspectives From Adult Metabolic Specialists on Newborn Screening for Inherited Metabolic Diseases.
J Inherit Metab Dis
July 2025
AP-HP, Pitié-Salpêtrière University Hospital, Department of Medical Genetics, Reference Centers for Adult Neurometabolic Diseases and Adult Leukodystrophies, Paris, France.
The number of inherited metabolic diseases (IMDs) in newborn screening (NBS) programs has increased significantly in the past decades. For some of the IMDs included in NBS (e.g.
View Article and Find Full Text PDFNitisinone desensitization protocol, case report of hereditary Tyrosinemia type 1 with successful treatment and outcomes.
Orphanet J Rare Dis
July 2025
Sociedad de Cirugía de Bogotá, Hospital de San José, Calle 10 # 18- 75, Bogotá, Colombia.
The third known case in the country of Tyrosinemia type 1 is presented, a 10-month-old male infant who was referred to the emergency room due to hepatomegaly, compromised liver function, neurological deterioration, and abnormal urinary amino acids findings. Given the persistence of hepatic deterioration and focal hepatic lesions, a high clinical suspicion of Tyrosinemia type 1 was considered, and targeted treatment with Nitisinone and a restrictive diet was initiated, resulting in an appropriate clinical and tests response. However, there was an abrupt discontinuation of the medication without any medical indication, added to the fact that elevated succinylacetone levels were later reviewed, the main diagnosis was confirmed.
View Article and Find Full Text PDFAre protein substitutes available in Italy for infants with inherited metabolic diseases all the same?
Front Nutr
May 2025
Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy.
Introduction: Inherited metabolic diseases (IMDs) represent a major clinical challenge, especially during the neonatal and infant periods. They require tailored and long-term nutritional management to ensure proper growth and development. Protein substitutes are essential in the dietary treatment of IMDs, particularly aminoacidopathies, organic acidemias, and urea cycle disorders.
View Article and Find Full Text PDF